These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24566868)

  • 1. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
    Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
    Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway.
    Zhao Y; Hong L
    Cancer Biother Radiopharm; 2021 Mar; 36(2):202-210. PubMed ID: 33156701
    [No Abstract]   [Full Text] [Related]  

  • 3. Rsf-1 Influences the Sensitivity of Non-Small Cell Lung Cancer to Paclitaxel by Regulating NF-κB Pathway and Its Downstream Proteins.
    Chen X; Sun X; Guan J; Gai J; Xing J; Fu L; Liu S; Shen F; Chen K; Li W; Han L; Li Q
    Cell Physiol Biochem; 2017; 44(6):2322-2336. PubMed ID: 29258089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
    Yang G; Xiao X; Rosen DG; Cheng X; Wu X; Chang B; Liu G; Xue F; Mercado-Uribe I; Chiao P; Du X; Liu J
    Clin Cancer Res; 2011 Apr; 17(8):2181-94. PubMed ID: 21339307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
    Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
    Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
    Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer.
    Chen Y; Johnson JD; Jayamohan S; He Y; Venkata PP; Jamwal D; Alejo S; Zou Y; Lai Z; Viswanadhapalli S; Vadlamudi RK; Kost E; Sareddy GR
    Mol Carcinog; 2024 Oct; 63(10):2026-2039. PubMed ID: 38990091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
    Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
    Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.
    Shuang T; Wang M; Zhou Y; Shi C; Wang D
    Oncotarget; 2017 Apr; 8(15):24853-24868. PubMed ID: 28206956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
    Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
    Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
    Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
    Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-kappa B for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-gamma gene.
    Hiroi M; Ohmori Y
    J Biol Chem; 2003 Jan; 278(1):651-60. PubMed ID: 12403783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.
    Xiaomeng F; Lei L; Jinghong A; Juan J; Qi Y; Dandan Y
    Braz J Med Biol Res; 2020; 53(6):e8885. PubMed ID: 32401925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way.
    Wang W; Gao Y; Hai J; Yang J; Duan S
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30314995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.